Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,263 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Copd Clear all
Completed No phase listed Observational Results available

Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness

NCT03543176
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI, FLUT/SAL, CAT, mMRC, Ellipta, Diskus
Other · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 28, 2026, 10:25 PM EDT
Completed Not applicable Interventional

Harmonica Playing Improves Quality of Life in Patients With COPD

NCT03442140
View directory record Official record
Conditions
COPD
Interventions
Harmonica playing
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
45 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 28, 2026, 10:25 PM EDT
Completed Phase 2 Interventional

Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency

NCT03114020
View directory record Official record
Conditions
Emphysema, Alpha 1-Antitrypsin Deficiency
Interventions
Hyaluronic Acid Inhalation Solution, Placebo Inhalation Solution
Drug
Lead sponsor
Gerard Turino
Individual
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Miami, Florida • Fayetteville, New York • Charleston, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 28, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

NCT01970878
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
GFF MDI (PT 003), GP MDI (PT001), FF MDI (PT005), Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
110
States / cities
Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 28, 2026, 10:25 PM EDT
Recruiting Phase 2 Interventional

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

NCT07059091
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Allergies
Interventions
Omalizumab (Xolair®), Sodium Chloride (NaCl) 0.9 %
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 28, 2026, 10:25 PM EDT
Completed Not applicable Interventional Results available

Macrolide Azithromycin to Prevent Rapid Worsening of Symptoms Associated With Chronic Obstructive Pulmonary Disease

NCT00325897
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Macrolide Antibiotic (Azithromycin), Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years and older
Enrollment
1,142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 28, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

Effect of Supplemental Vitamin D on Skeletal Muscle Function in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT00914810
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Vitamin D (cholecalciferol), Placebo
Dietary Supplement
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
40 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Oct 28, 2026, 10:25 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers

NCT04722835
View directory record Official record
Conditions
Copd, Smoking, Tobacco Use
Interventions
Bronchoscopy with Bronchoalveolar Lavage (BAL)
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2030
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 28, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).

NCT01218126
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
losmapimod, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Birmingham, Alabama • Torrance, California • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 28, 2026, 10:25 PM EDT
Terminated Phase 3 Interventional

Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)

NCT00662740
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium/Salmeterol QD, Placebo, Salmeterol, Tiotropium/Salmeterol QD+ Salmeterol, Tiotropium (Spiriva®)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
20
States / cities
Boulder, Colorado • Wheat Ridge, Colorado • Winter Park, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 28, 2026, 10:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

SNORE (Smartphone Analyses of Nocturnal Obstruction by Respiratory Evaluation) SOUNDS

NCT03288376
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
Incyphae, Inc.
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
Burlingame, California • New London, Connecticut • Lanham, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 28, 2026, 10:25 PM EDT
Completed No phase listed Observational

Enhancing Utilization of Non-Invasive Positive Pressure Ventilation in Critical Care

NCT00458926
View directory record Official record
Conditions
COPD, Congestive Heart Failure, Asthma, Respiratory Distress Syndrome, Adult, Pneumonia
Interventions
Not listed
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2023 · Synced Oct 28, 2026, 10:25 PM EDT
Completed Not applicable Interventional Results available

Non-invasive Ventilation System in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01355978
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Airflow Obstruction, Chronic, Chronic Obstructive Airway Disease, Chronic Obstructive Lung Disease
Interventions
Noninvasive Open Ventilation System
Device
Lead sponsor
Breathe Technologies, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
3
States / cities
Concord, California • San Diego, California • Ogden, Utah
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Oct 28, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

NCT01387230
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Sunset, Louisiana • Easley, South Carolina • Spartanburg, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 28, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B

NCT01323660
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719 125, GSK573719 62.5, GW642444 25, placebo
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older · Male only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
Jasper, Alabama • Torrance, California • Fort Collins, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 28, 2026, 10:25 PM EDT
Not listed Phase 2 Interventional

Biological Effects of Quercetin in COPD Phase II

NCT06003270
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Emphysema, Chronic Bronchitis With Airway Obstruction
Interventions
Quercetin 1000 mg, Quercetin 500 MG, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 28, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)

NCT02105961
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Mepolizumab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
35
States / cities
Birmingham, Alabama • Mobile, Alabama • Riverside, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 28, 2026, 10:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Casein Protein and Leucine Supplementation in Chronic Obstructive Pulmonary Disease (COPD)

NCT01734473
View directory record Official record
Conditions
COPD
Interventions
Hydrolyzed casein protein, Hydrolyzed casein protein + carbohydrates, Hydrolyzed casein protein + leucine, Hydrolyzed casein protein + carbohydrates + leucine, 4 levels of hydrolyzed casein protein + carbohydrates
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 28, 2026, 10:25 PM EDT
Completed No phase listed Observational

Changes in Cytokine Levels During an Acute Exacerbation of Chronic Obstructive Pulmonary Disease

NCT00281242
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive
Interventions
blood draw
Other
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 28, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations

NCT01120691
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
QVA149, NVA237, tiotropium, Salbutamol/albuterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
2,224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
53
States / cities
Birmingham, Alabama • Fairhope, Alabama • Florence, Alabama + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Oct 28, 2026, 10:25 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Study to Investigate Small Mobile Stem Cells (SMS) in Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT07871890
View directory record Official record
Conditions
Chronic Obstructive Lung Disease
Interventions
Stem cells
Biological
Lead sponsor
SMSbiotech
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 10:25 PM EDT
Terminated Not applicable Interventional Results available

Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study

NCT01608490
View directory record Official record
Conditions
Emphysema
Interventions
RePneu Lung Volume Reduction Coil System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
35 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • Mountain View, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 28, 2026, 10:25 PM EDT
Completed No phase listed Observational

Innate Immune Response in COPD

NCT02637219
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Immunity, Innate, Inflammation, Bronchitis, Chronic, Toll-Like Receptors
Interventions
Not listed
Lead sponsor
VA Puget Sound Health Care System
Federal
Eligibility
50 Years to 89 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Oct 28, 2026, 10:25 PM EDT
Completed No phase listed Observational

EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)

NCT06742736
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BGF
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
13,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 28, 2026, 10:25 PM EDT